(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 September 2023 (21.09.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/174897 A1

(51) International Patent Classification:
C07K 16/18 (2006.01) *A61K 39/00* (2006.01)
C07K 16/30 (2006.01) *C07K 14/725* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/EP2023/056397

(22) International Filing Date:
14 March 2023 (14.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
22161839.0 14 March 2022 (14.03.2022) EP

(71) Applicants: **HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)** [DE/DE]; Ingolstaedter Landstrasse 1, 85764 Neuherberg (DE). **EXIMMIUM BIOTECHNOLOGIES GMBH** [DE/DE]; Feodor-Lynen-Strasse 21, 81377 Munich (DE). **KLINIKUM DER UNIVERSITAET MUENCHEN** [DE/DE]; Anstalt des oeffentlichen Rechts, Marchioninistrasse 15, 81377 Munich (DE).

(72) Inventors: **ZEIDLER, Reinhard**; Mathias-Duschl-Strasse 15F, 82140 Olching (DE). **GAERTNER, Kathrin**; St.-Quirin-Platz 1, 81547 Munich (DE).

(74) Agent: **WEINZIERL, Gerhard** et al.; c/o Schiweck Weinzierl Koch, Ganghoferstrasse 68b, 80339 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2023/174897 A1

(54) Title: COMPOSITION COMPRISING AN ANTIBODY WHICH BINDS TO HUMAN SRRM2 PRESENT ON THE CELL SURFACE OF A TARGET CELL

(57) Abstract: The present invention provides a pharmaceutical composition comprising an antibody, which binds to human SRRM2 present on the cell surface of a target cell and optionally a pharmaceutically acceptable carrier, diluent or excipient. The present invention further provides said pharmaceutical composition for use in a method for the treatment of cancer in a human subject. Further is provided a method for determining whether a human subject may suffer from cancer, comprising determining in a sample obtained from said human subject whether SRRM2 is present on the cell surface of cells comprised by said sample. Additionally, an antibody, which binds to human SRRM2 present on the cell surface of a target cell is provided and an antibody, which binds to human SRRM2 present on the cell surface of a target cell for use in a method of killing said target cell having human SRRM2 present on the cell surface.